![](https://investorshub.advfn.com/uicon/334928.png?cb=1606947403)
Monday, November 17, 2014 9:12:52 AM
8:40a ET November 17, 2014 (Benzinga)
Analysts at Canaccord Genuity initiated coverage on shares of Mast Therapeutics (NYSE: MSTX) with a Buy rating.
The target price for Mast Therapeutics is set to $3.
Mast Therapeutics' shares jumped 11.11% to $0.50 in pre-market trading.
Latest Ratings for MSTX DateFirmActionFromTo
Nov 2014Canaccord GenuityInitiates Coverage onBuy Oct 2013Canaccord GenuityInitiates Coverage onBuy
View More Analyst Ratings for MSTX
View the Latest Analyst Ratings
Recent MSTX News
- NYSE and Nasdaq Pull ETF Options Requests, 75% of Bitcoins Remain Inactive, MakerDAO Halts WBTC Loans • IH Market News • 08/16/2024 07:25:47 PM
- Deutsche Bank Faces Shareholder Backlash, Bank of America Sponsors 2026 World Cup, Quanterix CEO Buys More Shares • IH Market News • 08/16/2024 10:03:21 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM